Our latest articles
J&J looks to be bolder on deals
Tuck-ins are the order of the day, although new chief doesn’t rule out a large buy.
Sierra’s not-so-nimble Jak scores at last
Momelotinib, a Jak inhibitor that has been through four companies, yields a positive result in its pivotal Momentum trial.
SFNP 2022 – Alnylam takes heart from its Onpattro follow-on
But further data do not shed much light on Onpattro’s chances in Apollo-B.
Asco-GI – immuno-oncology makes progress in liver cancer
Astrazeneca looks to enter a field in which Merck & Co recently tripped up, and in which Roche is the only IO player.
Medical device groups float – then sink
Medtechs rushed for the markets last year, but had an uneasy time once there.
UCB makes a rare acquisition
The Belgian group has bolstered its epilepsy offering with a $1.9bn move on Zogenix.
Cytokinetics hopes to resurrect omecamtiv
Almost in stealth mode, Cytokinetics has pressed on with the heart failure project, which now awaits a key regulatory catalyst.
Device makers buy big
Whether sitting on a pile of cash or guarding against growing pressures, acquisitions are the answer.
